PGR and breast cancer: Alterations in the IGF1Rβ/IR system signalling have been reported in models of endocrine resistance in vitro35,36 and here we build on this to show that this similarly occurs in both ER+/PR+ PDX (Fig. 1) and ER+/hyperactive-PR+ breast cancer models (Fig. 3).